FDA QMSR: What Changed in 21 CFR Part 820
The FDA's Quality Management System Regulation (QMSR) is the current version of 21 CFR Part 820. It took effect on February 2, 2026, replaced the old Quality System (QS) regulation, and incorporates ISO 13485:2016 by reference. If you make finished medical devices for the US market, your quality system is now inspected against ISO 13485 plus a short list of FDA-specific requirements.
The QMSR has been in force for most of 2026, so the question for most teams is no longer "what's coming?" It's "did we actually close the gaps?" This guide covers what changed in Part 820, where each old QS section now lives in ISO 13485, the FDA requirements ISO doesn't cover, how inspections changed, and a gap-check you can run against your own system.
What is 21 CFR Part 820 now?
Part 820 sets the current good manufacturing practice (CGMP) requirements for finished devices intended for human use. Under the QMSR, it's a much shorter regulation. Instead of spelling out requirements section by section, the current Part 820 has a handful of sections:
The rest of the familiar section numbers, from 820.20 to 820.250, are now reserved. The requirements didn't disappear; they moved into ISO 13485.
Who it applies to
The QMSR covers manufacturers of finished devices, including contract sterilizers, relabelers, remanufacturers, repackagers and specification developers. Under §820.1(a)(2), it does not apply to manufacturers of components or parts of finished devices, although FDA encourages them to consider it. A manufacturer only has to meet the requirements that apply to the operations it actually performs.
What changed from the QS regulation to the QMSR
FDA published the final rule on February 2, 2024 (89 FR 7496) with a two-year transition. These are the changes that matter most in day-to-day quality work.
ISO 13485 is now the backbone
Section 820.10(a) requires you to document a quality management system that complies with ISO 13485 and the other applicable requirements of Part 820. FDA's own term "safety and effectiveness" still governs: §820.3(b) says ISO's "safety and performance" has the meaning of safety and effectiveness, and that "organization" means "manufacturer."
FDA certificates don't exist, and ISO certificates don't exempt you
FDA's QMSR FAQ is clear on two points: FDA will not require or issue ISO 13485 certificates, and a certificate of conformance to ISO 13485 will not exempt a manufacturer from an FDA inspection. The final rule also notes that compliance with ISO 13485 alone does not fully satisfy the QMSR. If you're also working toward certification, our guide to ISO 13485 certification covers that path separately.
DMR, DHR and DHF are gone as named records
The QMSR drops the device master record, device history record, design history file and quality system record as separate required record types. The content mostly lives on under ISO 13485 names: the medical device file (clause 4.2.3), the record for each device or batch (clause 7.5.1), and the design and development file (clause 7.3.10). Expect auditors to look for the content, not the old labels.
Management reviews, internal audits and supplier audits are now inspectable
This is the change with the most practical bite. Under the old QS regulation, §820.180(c) kept management review, quality audit and supplier audit reports out of routine FDA inspection. That exception is not in the QMSR. FDA's FAQ confirms the agency now has authority to inspect these records, and that records created before February 2, 2026 can also be reviewed.
If your management review minutes or internal audit reports were written on the assumption that FDA wouldn't read them, they deserve a second look.
Risk management carries more weight
ISO 13485 builds risk-based thinking into the QMS, including documented risk management in product realization. FDA did not incorporate ISO 14971 by reference (final rule, comment 9), but your risk management process still has to satisfy ISO 13485, and most teams use ISO 14971 to do it.
Where the old QS sections live now
FDA declined to publish an official one-to-one crosswalk, saying in the final rule that it would be cumbersome and not a useful tool. Still, most teams need one to update procedure references. The table below is a practical starting point for finding where a familiar QS topic now sits in ISO 13485:2016. Always confirm against the standard itself.
Your existing work on topics like nonconforming product under 21 CFR 820 or CAPA still applies. What usually needs updating is the citation in your procedures and the record names your teams use.
What ISO 13485 doesn't cover: the FDA-specific requirements
This is where teams that were already ISO 13485 certified tend to have gaps. Part 820 adds the following on top of the standard.
Part 820 also supplements other FDA regulations rather than replacing them (§820.1(b)). Requirements in separate parts, such as 21 CFR Part 11 for electronic records and signatures, still apply.
How FDA inspections changed
On February 2, 2026, FDA stopped using the Quality System Inspection Technique (QSIT) for device inspections. According to FDA's QMSR page, inspections now follow the updated compliance program 7382.850, Inspection of Medical Device Manufacturers, which replaced programs 7382.845 and 7383.001.
Two practical consequences:
Inspections are still scheduled based on risk, and the Medical Device Single Audit Program (MDSAP) remains available as a voluntary third-party audit program. Your QMS is only one part of getting a device to market; premarket pathways are covered in our guide to regulatory strategy.
QMSR gap check: 10 questions to ask your quality system
FDA says it can't advise each organization on how to evaluate its QMS, so here is a practical checklist. If you can answer yes to each, you're in good shape for an inspection under the QMSR.
Work through the list against your actual records, not just your SOPs. Gaps tend to show up where a procedure was updated but the forms people use every day weren't.
Managing QMSR evidence in Isolocity
Most of the checklist above comes down to connected records: controlled procedures, the training that goes with them, and the complaints, nonconformances and audits that prove the system works. The Isolocity platform is built for life sciences teams working to ISO 13485, MDSAP and GxP, and its life science QMS is compliant with FDA 21 CFR Part 11 and Annex 11.
FAQ
What is 21 CFR Part 820?
21 CFR Part 820 is the FDA regulation that sets quality management system requirements for manufacturers of finished medical devices sold in the US. Since February 2, 2026, it's called the Quality Management System Regulation (QMSR) and incorporates ISO 13485:2016 by reference.
When did the QMSR take effect?
February 2, 2026. FDA published the final rule on February 2, 2024, and FDA began enforcing the QMSR requirements on the effective date.
Is the QS regulation still in effect?
No. The QMSR amended Part 820 and replaced the QS regulation. Sections such as 820.30, 820.90 and 820.100 are now reserved, and their topics are covered by ISO 13485 clauses.
Do I need ISO 13485 certification to comply with the QMSR?
No. FDA doesn't require ISO 13485 certification and doesn't issue certificates. A certificate also won't exempt you from FDA inspection. What FDA requires is a QMS that complies with ISO 13485 and the rest of Part 820.
Does Part 820 apply to component manufacturers?
No. Section 820.1(a)(2) says Part 820 doesn't apply to manufacturers of components or parts of finished devices, though FDA encourages them to consider its provisions. Your device customers will usually still apply purchasing controls to you under ISO 13485 clause 7.4.
Conclusion
The QMSR didn't change what good device quality looks like, but it did change the language, the record names and what an investigator can ask to see. The teams that struggle are the ones whose procedures were updated on paper while the records behind them still assume the old rules. If you'd like to see how Isolocity keeps procedures, training, complaints, CAPAs and audits connected for an FDA inspection, book a demo.






